Inactive Instrument

Cosmo Pharmaceuticals S.p.A Stock Deutsche Boerse AG

Equities

IT0004167463

Pharmaceuticals

End-of-day quote Deutsche Boerse AG
- EUR - Intraday chart for Cosmo Pharmaceuticals S.p.A
Sales 2024 * 249M 272M Sales 2025 * 220M 240M Capitalization 1.17B 1.27B
Net income 2024 * 113M 123M Net income 2025 * 74M 80.7M EV / Sales 2024 * 4.07 x
Net cash position 2024 * 155M 169M Net cash position 2025 * 220M 240M EV / Sales 2025 * 4.32 x
P/E ratio 2024 *
9.58 x
P/E ratio 2025 *
12.9 x
Employees -
Yield 2024 *
2.4%
Yield 2025 *
1.59%
Free-Float 44.36%
More Fundamentals * Assessed data

Latest transcript on Cosmo Pharmaceuticals S.p.A

Managers TitleAgeSince
Director of Finance/CFO 52 16-05-31
Chairman 61 05-12-31
Chief Tech/Sci/R&D Officer 54 -
Members of the board TitleAgeSince
Founder 69 96-12-31
Director/Board Member 69 12-03-31
Chairman 61 05-12-31
More insiders
Cosmo Pharmaceuticals N.V. is a pharmaceutical company. The Company is focused on gastrointestinal (GI) diseases and dermatology. Its development pipeline is focused on Bowel Diseases, Colon Infections, and products to reduce the incidence of Colorectal Cancer (CRC) by increasing the detection of cancerous and pre-cancerous lesions during colonoscopy. Products which it has developed include Lialda/Mezavant/Mesavancol and Uceris/Cortiment, for the treatment of ulcerative colitis; GI Genius, which uses artificial intelligence to aid the detection of colorectal polyps during colonoscopy; Eleview, a submucosal injectable composition for use in gastrointestinal endoscopic procedures; Aemcolo for the treatment of travellers’ diarrhoea (TD), Methylene Blue MMX, which is a new diagnostic drug to improve precancerous and cancerous lesion detection during colonoscopy and Winlevi for the treatment of acne. Its therapeutic focus is on the oral and endoscopic treatment of colon diseases.
Calendar
More about the company